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expected extent for a medical condition and a pharmaceutical treatment, 
respectively; and the independent variables were types of medical condition  
or pharmaceutical treatment, types of information sources, frequency of past 
information search, health, extraversion, gender, and metropolitan statistical 
area. RESULTS: A total of 505 consumers yielded complete interviews, with  
a cooperation rate of 37.4%. On average, they were 57 years old, and 61% of them 
were female. Twenty percent of them had expectations of seeking information 
for a medical condition, and 14% for a pharmaceutical treatment. All regressions 
were significant (p<0.01). Health and gender were significant predictors  
for expected likelihood, and health and extraversion were significant predictors 
for expected extent (p<0.05). CONCLUSIONS: As perceived health status 
worsened, consumers were not only more likely to search for information, but 
also to a larger degree. Women were more likely to search for information, and 
those who were outgoing tended to perform information search to a larger 
degree.  
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DIFFERENT STAKEHOLDER PERSPECTIVES ON PHARMACOGENOMIC TESTING  
Patel H, Ursan I, Zueger P, Pickard AS 
University of Illinois at Chicago, Chicago, IL, USA  
OBJECTIVES: Although the potential benefits of pharmacogenomic (PG) testing 
may be readily evident, there are numerous concerns creating barriers to its 
implementation. The purpose of our study was to compare various stakeholder 
attitudes and concerns toward PG testing as identified from the literature. A sub-
aim was to understand issues with PG testing identified by underrepresented 
groups. METHODS: Using specific keywords, we conducted a systematic 
literature search of electronic databases including PubMed, IPA, CINAHL, and 
EMBASE. Articles that evaluated the attitudes and beliefs about PG testing were 
included. Concerns identified in the studies were categorized into themes 
(ancillary information-related, clinical, economical, educational, ethical/legal, 
medical mistrust, and operational), and summarized according to stakeholder 
group (patients, general public, providers, payers and others). RESULTS: Of 1483 
citations identified in the initial search, 38 studies that presented 41 perspectives 
met the inclusion criteria, employing methods of eliciting perceptions via 
surveys, focus groups and interviews. Overall, there were 15 studies focusing on 
providers, 9 on general public, 9 on patients, and 4 on payers, and 4 on other 
stakeholder perspectives. Studies of the general public most commonly 
identified issues related to medical mistrust (n=5), education (n=5) and 
operations (n=5). The most prevalent issues from the patient perspective 
included ethical/legal (n=6) and economical (n=5). Clinical (n=11) and educational 
(n=11) issues related to PG testing were recognized as frequent among the 
providers. Among the payer perspective, operational (n=4) and clinical (n=3) 
issues were prominent. In the underrepresented groups, concerns of medical 
mistrust and economical issues were notably higher compared to other groups. 
CONCLUSIONS: While the number of studies, assessing attitudes and concerns 
of various stakeholders, has increased over the last five years, the fundamental 
issues remain unchanged. Improved understanding of such issues may help 
strengthen the uptake of pharmacogenomic testing in clinical practice and lead 
to better health outcomes.  
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PUBLIC ENGAGMENT MECHANISMS IN HEALTH TECHNOLOGY ASSESSMENT 
(HTA): AN EARLY ASSESSMENT OF CANADA'S NATIONAL HTA PUBLIC 
ENGAGEMENT INITIATIVES  
Tran JB 
Double Helix Consulting, London, UK  
OBJECTIVES: To address questions about the importance of public (patients, 
patient groups, etc) engagement in HTA processes with the objective to – 1) 
explore ideas regarding the use of public engagement in decision making 
processes (specifically coverage decisions), and 2) contextualise some of  
the main arguments found by assessing the Canadian Agency for Drugs and 
Technologies in Health’s (CADTH) current public engagement mechanisms for  
its Common Drug Review (CDR). METHODS: A literature search was performed to 
identify key theoretical arguments for and against public engagement in HTA 
processes. The search was mainly focused on sources from Canada and the UK. 
A review of CADTH’s website was conducted for technology appraisals 
completed by the CDR process since the start of its public engagement initiatives 
(to mid-August 2012). RESULTS: Key arguments for public engagement in 
decision making include: transparency, accountability, equity, and creating a 
patient-centric health system. With the CDR, the percentage of appraisals 
conducted for coverage decisions that included public (patient group) input was 
48%. The lack of engagement from patient groups on half of the appraisals 
highlights some of the key challenges of public engagement (e.g., lack of 
awareness, lack of budget). Furthermore, the documents reviewed showed that 
some indications received more responses than others (e.g., epilepsy, 
schizophrenia). This may potentially result in some underfunded patient groups 
feeling disempowered, which is a risk of engagement. CONCLUSIONS:  
The findings of the study support initiatives that encourage the engagement  
of the public so that decision makers can better incorporate the values held  
by citizens. However, the relative value of doing so will vary. To ensure that 
public engagement in HTA is appropriate and fair, Canada and other 
jurisdictions must have political will, dedicated resources, and the motivation to 
facilitate educational activities that support active engagement from all types of 
public.  
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OBJECTIVES: To examine the impact of cost-sharing on the demand for 
medication across several classes of prescription medications indicated to treat 
chronic conditions. METHODS: Data from the 2005-2009 MarketScan Commercial 
Claims and Encounters databases were used to evaluate prescription fills across 
10 categories of medications. The date of first fill served as the index date for 
each subject and patterns of use were analyzed for at least seven continuous 
calendar quarters within the study window. Cost sharing, expressed as a price 
index for each medication class, was the main explanatory variable to examine 
price elasticity of demand. This index was based on the average cost-sharing 
amount per prescription and was weighted using the national proportion of 
generic and brand medication within each drug category. Negative binomial 
generalized estimating equations models were constructed to examine 
medication fills; standard demographic variables were used to control for 
confounding. RESULTS: Prescription fills per enrollee ranged from 0.01 (smoking 
deterrents) to 0.23 (Statins) and the average spending for medications showed 
considerable variability: those taking thyroid hormone reported an average 
expenditure of $31.29 while those on antiplatelets had an average expenditure of 
$330.38. Additionally, the share of generic drug use within each category ranged 
from 4.7% (smoking deterrents) to 88.4% (NSAIDs/Opioids). Estimates from the 
negative binomial models revealed that the price elasticity of demand ranged 
from -0.015 to -0.157 within the 10 categories of medications (p<0.05 for 9 of 10 
categories). Demand for smoking deterrents proved to be the most price elastic 
of drug categories (-0.157), while NSAIDs/Opioids were observed to be relatively 
price inelastic (-0.015). CONCLUSIONS: The price elasticity of demand varied 
considerably by medication category, suggesting that the influence of cost-
sharing on medication use may be related to characteristics inherent to each 
medication class or underlying condition.  
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AN ANALYSIS OF THE RELATIONSHIP BETWEEN GROWTH IN PATIENT COST 
SHARING DUE TO BENEFIT DESIGN SHIFTS AND DIAGNOSTIC PRICING AND 
SPENDING  
Abraham J, Garfield S, Sulham K 
GfK Bridgehead, Wayland, MA, USA  
OBJECTIVES: Consumers are shouldering an increasing percentage of health care 
expenditures through cost-sharing mechanisms embedded in benefit design 
structures. As a result, many patients are paying out-of-pocket for some or all of 
the costs associated with diagnostic testing. Traditionally, diagnostic companies 
have focused on demonstrating value to payers with the goal of achieving 
adequate pricing and reimbursement. Though this approach will remain 
necessary, patients are an increasingly critical stakeholder in determining 
whether a diagnostic’s value supports the resulting out-of-pocket costs. This 
study examined how out-of-pocket expenditures by individuals, national health 
expenditures (NHE) on diagnostics, and the price index for diagnostics grew 
between 2005 and 2011. METHODS: A systematic review of published literature 
related to health care expenditure, health insurance coverage, diagnostic pricing, 
and benefit design was performed. In follow-up, data from the Centers for 
Disease Control and Prevention, Bureau of Labor Statistics, Employer Benefits 
Health Survey, and diagnostic industry reports were reviewed to examine growth 
rates over the study period. Basic statistical methods were employed to 
determine how average annual growth rates within each segment relate to other 
variables being considered. RESULTS: The proportion of individuals in America 
with high-deductible health plans has increased 475% in the last six years. This 
correlates to over 25 million Americans responsible for at least $2000 in 
deductible costs in addition to coinsurance and co-pays. During this period, 
pricing of diagnostics only rose at an average annual rate of 1.0%. Overall 
spending on health care increased while diagnostics expenditure remained 
consistent at 6% of NHE. CONCLUSIONS: As health care continues to transform, 
the demand for high quality diagnostics will continue to grow. However, the 
increasing financial burden borne by individuals will lead to increased price 
sensitivity. Novel technologies will need to demonstrate value and clinical utility 
not only to payers, but to patients, to achieve pricing and reimbursement.  
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RACIAL DISPARITY IN DURATION OF PATIENTS' VISITS TO THE EMERGENCY 
DEPARTMENT: TEACHING VERSUS NON-TEACHING HOSPITALS  
Wong H, Karaca Z 
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OBJECTIVES: Racial disparity in duration of patients’ visits to emergency 
departments (EDs) have not been well documented. This study explores the 
racial disparity in duration of routine visits to EDs at teaching and non-teaching 
hospitals. METHODS: Retrospective data analyses and multivariate regression 
analyses were performed to investigate the racial disparity in duration of routine 
ED visits at teaching and non-teaching hospitals. Duration for each visit was 
computed by taking the difference between admission and discharge times. The 
Healthcare Cost and Utilization Project (HCUP) State Emergency Department 
Databases (SEDD) were used in the analyses. The data include 4.3 million routine 
ED visits encountered in Arizona, Massachusetts, and Utah during 2008. SEDD 
provide detailed diagnoses, procedures, total charges, patient demographics, and 
admission and discharge time for each visit. We linked SEDD files with American 
Hospital Association Annual Survey Database, Trauma Information Exchange 
Program Database and Area Resource File to obtain hospital and area level 
characteristics. RESULTS: The mean duration for a routine ED visit was 238 
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minutes at teaching hospitals and 175 minutes at non-teaching hospitals. There 
were significant variations in duration of routine ED visits across race groups at 
teaching and non-teaching hospitals. The risk-adjusted results show that the 
mean duration of routine ED visits for black/African American and Asian 
patients when compared to visits for white patients was shorter by 10.0 and 3.4 
percent, respectively, at teaching hospitals; and longer by 3.6 and 13.8 percent, 
respectively, at non-teaching hospitals. Hispanic patients experienced 8.7 
percent longer ED stays when compared to white patients at non-teaching 
hospitals. CONCLUSIONS: There is significant racial disparity in the duration of 
routine ED visits, especially in non-teaching hospitals where non-white patients 
experience longer ED stays compared to white patients. The variation in duration 
of routine ED visits at teaching hospitals when compared to non-teaching 
hospitals was smaller across race groups.  
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OBJECTIVES: The Italian National Health Service (Servizio Sanitario Nazionale-SSN) 
is structured on two levels: the national and regional level. The national 
government defines the benefits package (essential levels of care, livelli essenziali 
di assistenza-LEA) to which citizens are constitutionally entitled and which each 
Regional Health Service (Servizio Sanitario Regionale-SSR) is responsible for. Since 
1997 the regions have been fully autonomous in organizing and managing their 
SSR, including the definition of DRG tariffs for hospital admissions. The aim of 
this study is compare the regional differences among tariffs for the main surgical 
DRGs of each Major Diagnostic Category (MDC). METHODS: In order to identify 
the surgical DRGs with the highest volumes for each MDC, we used the dataset 
of admissions registered in 2010 by all hospitals (DRG version 24 ICD9-CM), 
published by the Italian Department of Health (Ministero della Salute), and we 
analyzed the variability among tariffs by calculating their average and standard 
deviations (the extra-reimbursement has not been considered). RESULTS: 
Average tariffs were calculated starting from the standard regional tariff for each 
DRG. Comparing the first 10 DRGs, we identified a variation in the average tariff 
which rose from -1.8% to +22.6% and a standard deviation with a minimum of 
425€ and a maximum of 1443€. Further complexity is given by the intra-regional 
variation by type of hospital, where we observed a variation inside the same 
region of 82% for the same DRG. CONCLUSIONS: The SSN is characterized by a 
high variability of regional DRG tariffs, also inside the regions. Moreover in Italy 
there is not a defined procedure to update the classification of DRGs and the 
related tariffs. Therefore there is a need to establish a systematic periodical 
review, which should involve all the different stakeholders of SSN, and to share 
data updated with them about the volume of admissions.  
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FINANCING METHOD IN THE HUNGARIAN DRG-BASED HOSPITAL 
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University of Pécs, Pécs, Hungary  
OBJECTIVES: The aim of our study was to investigate the financial effects of 
switching from the so-called performance volume limit (PVL) to degressive 
financing method in the Hungarian DRG-based hospital financing. METHODS: 
The data in our analysis were derived from the nationwide administrative 
dataset of the National Health Insurance Fund Administration (OEP), the only 
health care financing agency. We examined mainly the period between 2009 and 
2012. The difference in hospital reimbursement between the preannounced DRG 
reimbursement rate and degressive cap (upper ceiling) was calculated both on 
national level and in the case of the Clinical Center of the University of Pécs. 
RESULTS: The ratio of partially paid [based on preannounced performance base-
fee (PPBF) or performance volume limit (PVL) financing method] active inpatient 
cost-weights to total cost-weights varied extremely between 2009-2012. In the 
case of PPBF financing in 2009, 25-30% of the total national performance fell 
under floating fee structure, resulting in a monthly change in the monetary 
(Hungarian Forint, HUF) value of a DRG cost-weight. In the case of degressive PVL 
from 2011 onwards, one to seven percent of the national performance fell in the 
degressive zone, with a prefixed value of HUF 45,000/cost-weighs. For the Clinical 
Centre of the University of Pécs, this partial reimbursement resulted in a large 
financial deficit in 2009, when PPBF was applied. In 2010 and 2011, the deficit of 
the University of Pécs lessened to some extent compared to 2009; however, it 
was still rather high (HUF 1.46 and HUF 1.3 billion, respectively). Due to partial 
health insurance reimbursement, the University of Pécs realized HUF 8.1 billion 
revenue losses between 2004 and 2012. CONCLUSIONS: Application of 
preannounced performance base-fee rendered institutional financing nearly 
incalculable. Renewed introduction of degressive performance volume limit in 
2011 made institutional financing more calculable; however, it failed to entirely 
stop source withdrawal.  
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TRENDS IN USE OF HEALTH ECONOMIC EVIDENCE FOR DEVELOPING CLINICAL 
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Aggarwal S, Topaloglu H, Kumar S, Segal J, McGrane M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: The recent reforms and policy changes have increased the cost 
pressures on all health care stakeholders, including clinical experts. In the past, 
clinical guidelines were developed independent of cost or economic 
considerations. However, increasingly, more clinical guidelines are mentioning 
cost concerns and referring to economic data in new recommendations. The 
objective of this study was to analyze trends in the use of health economic 
information for developing clinical guidelines. METHODS: To understand trends 
in use of health economic information we conducted targeted search for clinical 
guidelines, expert recommendations, and consensus statements with specific 
mention of “cost” or “economic” or related terms. A systematic literature search 
was undertaken for the databases Pubmed, Google Scholar and Cochrane. The 
guidelines published between 2003-2012 were included. For guidelines which 
met the search criteria, data was collected for the name of the authors, 
indication, year of publication, country/region, and context of use of 
cost/economic evidence. RESULTS: Sixteen clinical guidelines published between 
2003-2012 met the inclusion criteria for specific mention of cost/economic 
evidence. More than 50% of these guidelines were published between 2006-2012. 
For indication, 3 out of 16 guidelines were for diabetes, while the rest were for 
different indications. In these16 guidelines “cost effectiveness” was mentioned 
14 times, either referencing cost-effectiveness data or to mention the importance 
of such data for selecting treatment options. The guidelines commonly cite high 
cost of disease or high economic burden as one of the considerations for 
developing new recommendations (11 out of 16). Another term that was 
commonly used by these guidelines was “cost-benefit,” which was mentioned 5 
times in these guidelines. Notably, QALY was rarely mentioned (1 out of 16 
times) in these guidelines. CONCLUSIONS: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and 
incorporate health economic information for developing new recommendations.  
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EXTENSIONS (1984-2012)  
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OBJECTIVES: The Drug Price Competition and Patent Term Restoration Act of 
1984 (Waxman- Waxman Act - WHA) established a patent extension system that 
allows sponsors of new drugs (NDAs) and biologic applications (BLAs) approved 
by Food and Drug Administration (FDA) to recover part of the patent time 
dedicated to clinical trials and to the FDA drug review process. The maximum 
extension is 5 years and the effective patent life from approval to patent 
expiration cannot exceed 14 years. We assessed the characteristic of drugs and 
biologics that had a patent extension in the period 1984-2012 and examined the 
patent life timeline from clinical trials to regulatory review, and from marketing 
authorization to patent expiration (i.e. effective patent life). METHODS: Data 
were derived from the FDA, the US Patent and Trademark Office, and the US 
Federal Register. Descriptive analyses were performed. T-test was used to assess 
differences in averages. Significant level was set at 0.05. RESULTS: The USPTO 
listed 499 pharmaceuticals with patent extensions in the study period; 453 NDAs 
(90.8%), 38 BLAs (7.6%), and 9 vaccines (1.8%). Drug regulatory and patent 
information was available for 323 pharmaceuticals (287 NDA, 32 BLA and 4 
vaccines). The average±stdev patent extension was 2.7±1.4 years (median=2.2 
years; 95% CI=2.62.8). The extension was longer for vaccines (3.7±1.3 years) than 
for NDAs (2.7±1.4 years) and BLAs (2.4±1.5 years). The average clinical trials time 
was 5.9±3.1 years, being similar for NDAs, BLAs and vaccines. The average FDA 
review time was 1.7±1.3 years (higher for vaccines 2.6±2.5 years). The average 
length of the effective patent life was 8.7±7.0 years without patent extensions 
and 11.7±6.8 years after the extensions. CONCLUSIONS: A large number of 
pharmaceuticals were granted patent extensions in the US. The WHA 
significantly increased the effective patent life of pharmaceuticals.  
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Jeon HR, Lim MK, Yu SY 
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OBJECTIVES: A budget impact analysis(BIA) is a useful tool for a health care 
decision maker in estimating the financial impact of the new technology. In 
Korea, the content and presentation of results of the BIA have been proposed but 
detailed guidance on methods for BIA are not yet available. To evaluate the 
international landscape of BIA guidance, we compared guidelines of BIA outside 
of Korea. METHODS: A literature review was performed. Research for guidelines 
was based on data published in latest official papers or reports from ISPOR and 
national institutes in Canada, Ireland, and Poland. RESULTS: In all guidelines, 
the recommended perspective was that of public purchaser. A time horizon of 2-
5 years was considered to be desirable. It was stated that data on a technology 
and its use should be included in BIA, which is helpful for decision makers. 
Published guidelines provided a similar description of target population, but it 
was different whether or not off-label usage of drugs was included in 
assumption of population size. The approaches to measurement and evaluation 
of costs varied in different regions. The costing included direct costs associated 
with the technology in four guidelines but items of other costs were specified 
